You are here:HomeLive TVVideosNewsOral Insulin Can Be A Blockbuster Opportunity: Kiran Mazumdar-shaw

Oral insulin can be a blockbuster opportunity: Kiran Mazumdar-Shaw


Biocon has just brought in Bristol Meyers as a partner for its oral insulin drug. Bristol will fund the clinical trials and, if successful, the rest of the deal will be triggered. Kiran Mazumdar-Shaw, CMD, Biocon, is hopeful of the same and thinks this is a blockbuster opportunity.

Social Sharing


  • NSE
  • BSE
Company Price (Rs.) CHG %
RALLIS 180.20 8.36%
MOTHERSUMI 263.65 5.14%
BATAINDIA 1,094.85 3.72%
EICHERMOT 6,285.90 3.61%
More from Top Gainers »
Don't Miss


Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2014. All rights reserved.